+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Enhanced brain delivery of deferasirox-lactoferrin conjugates for iron chelation therapy in neurodegenerative disorders: in vitro and in vivo studies



Enhanced brain delivery of deferasirox-lactoferrin conjugates for iron chelation therapy in neurodegenerative disorders: in vitro and in vivo studies



Molecular Pharmaceutics 10(12): 4418-4431



Oxidative stress associated cell damage is one of the key factors in neurodegeneration development and is highly related to the presence of transition metal ions including iron. Herein, deferasirox, a high affinity iron chelator, was conjugated to lactoferrin molecules by carbodiimide mediated coupling reaction to create a novel drug delivery system with higher brain permeability through receptor mediated transcytosis. Each lactoferrin molecule was averagely attached to 4 to 6 deferasirox molecules resulting in water-soluble conjugated nanostructures which were purified and characterized. Neuroprotective effects of lactoferrin conjugated nanostructures and their cellular uptake were evaluated in differentiated PC12 cell line, and the molecular mechanisms involved in such neuroprotection were elucidated. Lactoferrin conjugates were able to interfere in apoptotic caspase cascade by affecting the expression level of caspase-3, PARP, Bax and Bcl-2. Furthermore, an elevation in the expression level of autophagy markers including Atg7, Atg12-Atg5 and LC3-II/LC3-I ratio was observed. Intraperitoneal injection of lactoferrin conjugates was able to significantly attenuate learning deficits induced by beta amyloid injection in a rat model of Alzheimer's disease, which further confirms a potential neuroprotective effect for lactoferrin conjugated deferasirox in neurodegenerative disorder management through metal chelation therapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 052982494

Download citation: RISBibTeXText

PMID: 24063264

DOI: 10.1021/mp4002014


Related references

Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets. Current Medical Research and Opinion 34(11): 1959-1966, 2018

Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. British Journal of Haematology 154(5): 654-656, 2011

Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis. Mediterranean Journal of Hematology and Infectious Diseases 6(1): E2014042-E2014042, 2014

Conjugates of superoxide dismutase 1 with amphiphilic poly(2-oxazoline) block copolymers for enhanced brain delivery: synthesis, characterization and evaluation in vitro and in vivo. Molecular Pharmaceutics 10(1): 360-377, 2013

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major. Clinics and Practice 7(1): 912-912, 2017

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload. Blood Research 49(1): 72-73, 2014

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Design, Development and Therapy 10: 465-481, 2016

Synthesis, in vitro kinetics, and in vivo studies on protein conjugates of AZT: evaluation as a transport system to increase brain delivery. Bioconjugate Chemistry 4(2): 139-145, 1993

Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia. Acta Haematologica 129(2): 72-77, 2013

Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrobial Agents and ChemoTherapy 53(7): 3122-3125, 2009

Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Current Medical Research and Opinion 24(6): 1609-1621, 2008

Restoration of hematopoiesis after iron chelation therapy with deferasirox in 2 children with severe aplastic anemia. Journal of Pediatric Hematology/Oncology 32(8): 611-614, 2010

Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI. Clinical Drug Investigation 30(4): 267-273, 2010

Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?. International Journal of Hematology 103(5): 537-544, 2016

Iron chelation therapy with deferasirox results in recovery of hematopoiesis in a child with aplastic anemia. Pediatric Hematology and Oncology 28(8): 718-720, 2012